Galectin‐1 as a therapeutic strategy and a biomarker for Alzheimer's disease

Abstract

Background: The rising prevalence of Alzheimer's disease (AD), the most preponderant form of dementia, represents a global health emergency. Early detection and novel therapeutic strategies are urgently needed due to the gradual progression of this neurodegenerative condition.